INTRODUCTION This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the objectives of our restructuring initiatives, including our future results, projected costs, prospects, plans and ...

Emergent BioSolutions Inc. (NYSE:EBS) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Haywood Miller - Interim Chief Executive Officer Paul Williams - Senior Vice President and Head, Product Business Rich Lindahl - Executive Vice President and CFO Conference Call Participants Nick Lorusso - TD Cowen Frank DiLorenzo - Singular Research Operator Good afternoon, everyone. I am the operator for today’s call. Thank you for joining today as Emergent discusses the Operational and ...

Q2 2023 Financial Results Update Introduction Q2 2023 Update PROPRIETARY AND CONFIDENTIAL 2 Safe Harbor Statement/Trademarks There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including, among others, the availability of USG funding for contracts related to procurement of our medical countermeasures, including CYFENDUSTM (Anthrax Vaccine Adsorbed (AVA), Adjuvanted), BioThrax® (Anthrax Vaccine Adsorbed) and ...

Emergent BioSolutions, Inc. (NYSE:EBS) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Company Participants Matt Hartwig - Investor Relations Haywood Miller - Interim Chief Executive Officer Richard Lindahl - Executive Vice President, Chief Financial Officer & Treasurer Paul Williams - Senior Vice President, Products Business Conference Call Participants Joichi Sakai - Singular Research Nicholas Lorusso - TD Cowen Operator Good day and thank you for standing by. Welcome to the Q2 2023 Emergent Bi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLUTIONS INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Or ...

Emergent BioSolutions Inc. (NYSE:EBS) Q1 2023 Earnings Conference Call May 9, 2023 5:00 PM ET Company Participants Bob Burrows - VP, IR Bob Kramer - President and CEO Paul Williams - Senior Vice President, Products Business Rich Lindahl - CFO Conference Call Participants Brandon Folkes - Cantor Fitzgerald Christopher Sakai - Singular Research Operator Good day, and thank you for standing by. Welcome to the Emergent BioSolutions First Quarter 2023 Financial Results Conference Call. At this time, all particip ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Gaithersburg, MD 20879 (Address and zip code of Principal Executive Offices) (240) 631-3200 (Registrant's Telephone Number, Including Area Code) Securities registered ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLUTIONS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 14-1902018 (State or Other Jurisdiction of Inc ...

Emergent BioSolutions Inc. (NYSE:EBS) Q4 2022 Earnings Conference Call February 27, 2023 5:00 PM ET Company Participants Bob Burrows - Vice President, Investor Relations Bob Kramer - President and CEO Rich Lindahl - Chief Financial Officer Conference Call Participants Nick Lenard - JPMorgan Brandon Folkes - Cantor Boris Peaker - Cowen Operator Good day and thank you for standing by. Welcome to the Emergent BioSolutions Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all pa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Gaithersburg, Maryland 20879 (Address and zip code of Principal Executive Offices) Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE A ...